CD33 and early-onset autosomal dominant Alzheimer disease: The only drug target indications missing included conditions not analysed in the MR study, such as CD33 protein being the drug target for treatment of leukaemia, with the exception of acetylcholinesterase whose inhibitors (galantamine, donepezil, rivastigmine) are used for treatment of cognitive decline in Alzheimer’s disease.40